Regeneron Pharmaceuticals (REGN) Long-Term Investments (2009 - 2026)

Regeneron Pharmaceuticals' Long-Term Investments history runs 18 years deep, the most recent figure standing at $9.8 billion for Q2 2026.

• In Q2 2026, Long-Term Investments fell 2.29% year-over-year to $9.8 billion; the TTM figure through Jun 2026 stood at $9.8 billion (down 2.29% YoY), while the FY2025 annual figure was $10.3 billion, up 15.29% from the prior year.
• Long-Term Investments for Q2 2026 stood at $9.8 billion, roughly flat from $9.8 billion in the prior quarter.
• The five-year high for Long-Term Investments was $10.3 billion in Q3 2025, with the low at $5.4 billion in Q4 2023.
• The 5-year median for Long-Term Investments is $7.4 billion (2022), against an average of $7.8 billion.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments soared 99.9% in 2022, then fell 18.13% in 2023.
• Regeneron Pharmaceuticals' Long-Term Investments stood at $6.6 billion in 2022, then fell by 18.13% to $5.4 billion in 2023, then surged by 64.92% to $8.9 billion in 2024, then rose by 15.29% to $10.3 billion in 2025, then slipped by 4.21% to $9.8 billion in 2026.
• Business Quant data shows REGN's Long-Term Investments at $9.8 billion in Q2 2026, $9.8 billion in Q1 2026, and $10.3 billion in Q4 2025.